[go: up one dir, main page]

AU1058797A - Treatment with calcium channel blockers for drug-induced hypersensitivity - Google Patents

Treatment with calcium channel blockers for drug-induced hypersensitivity

Info

Publication number
AU1058797A
AU1058797A AU10587/97A AU1058797A AU1058797A AU 1058797 A AU1058797 A AU 1058797A AU 10587/97 A AU10587/97 A AU 10587/97A AU 1058797 A AU1058797 A AU 1058797A AU 1058797 A AU1058797 A AU 1058797A
Authority
AU
Australia
Prior art keywords
drug
treatment
calcium channel
channel blockers
induced hypersensitivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10587/97A
Inventor
Frank S. Castellana
Agis Kydonieus
John J Wille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU1058797A publication Critical patent/AU1058797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU10587/97A 1995-11-22 1996-11-20 Treatment with calcium channel blockers for drug-induced hypersensitivity Abandoned AU1058797A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56181495A 1995-11-22 1995-11-22
US561814 1995-11-22
PCT/US1996/018760 WO1997018782A1 (en) 1995-11-22 1996-11-20 Treatment with calcium channel blockers for drug-induced hypersensitivity

Publications (1)

Publication Number Publication Date
AU1058797A true AU1058797A (en) 1997-06-11

Family

ID=24243586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10587/97A Abandoned AU1058797A (en) 1995-11-22 1996-11-20 Treatment with calcium channel blockers for drug-induced hypersensitivity

Country Status (2)

Country Link
AU (1) AU1058797A (en)
WO (1) WO1997018782A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2793681B1 (en) 1999-05-18 2001-06-22 Oreal USE OF AT LEAST ONE INHIBITOR OF AT LEAST ONE CALCIUM CHANNEL IN THE TREATMENT OF WRINKLES
FR2866810B1 (en) * 2004-03-01 2006-04-28 Oreal USE OF AT LEAST ONE CALCIUM CHANNEL INHIBITOR FOR PREVENTING AND / OR TREATING FAT SKIN.
US7399493B2 (en) 2004-07-16 2008-07-15 Wille John J Anti-irritant botanicals
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
WO2006127905A2 (en) 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Portable drug delivery device
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst Compositions and methods for treatment of symptoms in parkinson's disease patients
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077054A (en) * 1987-03-09 1991-12-31 Alza Corporation Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US4897260A (en) * 1987-05-22 1990-01-30 The Rockefeller University Compositions that affect suppression of cutaneous delayed hypersensitivity and products including same
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition

Also Published As

Publication number Publication date
WO1997018782A1 (en) 1997-05-29

Similar Documents

Publication Publication Date Title
AU7288696A (en) Vapor-permeable shoe
AU6107096A (en) Osmotic-delivery devices having vapor-permeable coatings
AU697308B2 (en) Statistical multiplexing
AU6212096A (en) Variable engagement toothbrush
GB9618783D0 (en) Dual spectrum illumination system
AU5341096A (en) Emergency lighting
AU5183496A (en) Polymeric composition
AU7698998A (en) Substituted peptidylamine calcium channel blockers
AU1058797A (en) Treatment with calcium channel blockers for drug-induced hypersensitivity
AU7088296A (en) Automatic bag-dispenser
AU2302297A (en) Cvt control system
AUPN871296A0 (en) Multicoat for light transmitting articles
AU7119596A (en) Rubber thread
EP0733850A3 (en) Luminary
GB9525880D0 (en) Channel
AU1552897A (en) Lace tensioning systems
AU5548596A (en) Candle
AU6475696A (en) Substituted phenols as novel calcium channel blockers
AU2611695A (en) Sailboatsystem for controlled gibing
AU2313797A (en) Overflow
AU1426197A (en) Process for the conversion of calcium sulfide
AU1185297A (en) Threaded fastener
AU7229696A (en) White stick for blind persons
AU5043196A (en) Fastening means
AU666457B3 (en) Profile